Neuritek Therapeutics is dedicated to develop breakthrough treatments for PTSD.
Neuritek's team dedicates passion, experience
and knowledge to treatment development in PTSD.
Leadership Team
Dr. William E. Hapworth M.D.
, President & Chairman of the Board
Dr. Hapworth has over 30 years psychiatry experience, and has treated more than 150K patients. He built the largest psychiatric practice in NYC and has been the Principal Investigator in numerous industry and investigator-initiated clinical trials. He has also been an Assistant Clinical Professor at NYU for over 25 years.
Allan Bradley
, Interim CEO / CFO & Director
Mr. Bradley has over 16 years of C level experience. He is a M&A, regulatory, strategic, capital and capital markets expert. Allan has managed international finance and operations teams and sits on the board of directors for two technology companies and a public oil and gas corporation.
Dr. Howard D. Uderman, M.D.
, Chief Medical Officer
A highly experienced doctor with over 40 years experience, holding positions in academia, medicine, and pharmaceuticals during his career. He has held instructor and professorship positions at institutions including Vanderbilt University, Princeton, and Yale-New Haven. For Pharma, he has worked with Bristol-Myers Squibb, Pfizer, and Non-Nordisk, Inc.
Margaret Courtney, PhD, Director of Pharmaceutical Development
Dr. Courtney has over twenty years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialization. She has worked in small and large pharmaceutical companies and following on from her doctoral studies has developed specific expertise in drug delivery systems.
Phil Taupin, MSC, DIBT, Director of Drug Safety
Phil Taupin is a general toxicologist with over 30 years experience in drug safety. He has held positions in a variety of CROs (such as Covance) and pharma (British Biotech, Celltech, UCB and Pfizer). He has comprehensive drug development experience, gained serving as the toxicologist on many project teams.
Clive Moore, PhD, Director, Project Management
Dr. Moore brings a wealth of Project Management experience, having been involved in managing both small and large scale projects in all phases of pharmaceutical development; from research, through development, and into commercialization. He has contributed to many other areas of the business including Supply Chain for commercial products, supporting the evaluation of new business opportunities, and being responsible for alliance management, both with partners and licensees.
Lesley Carmody, Qualified Person (QP) Consultant
Lesley has worked for large Pharma (Abbott Laboratories, Pfizer, and Bayer) and Contract Manufacturing Organizations, as well as starting her own Consultancy Business in 2003. In 2004, Lesley obtained her EU QP status (European Qualified Person) and is now named on two MIA (Investigational Medicinal Product, IMP) Licenses where she released batches of IMP to clinical trials. Lesley's main area of expertise lies in the supply chain process, consisting of clinical supplies packaging, labelling, storage, and distribution. She is also an experienced Lead Auditor with extensive knowledge of GxP auditing, and will serve in these functions for Neuritek.
Board of Directors
Dr. William E. Hapworth M.D.
, President & Chairman of the Board
Dr. Hapworth has over 30 years psychiatry experience, and has treated more than 150K patients. He built the largest psychiatric practice in NYC and has been the Principal Investigator in numerous industry and investigator-initiated clinical trials. He has also been an Assistant Clinical Professor at NYU for over 25 years.
Allan Bradley
, Interim CEO / CFO & Director
Mr. Bradley has over 16 years of C level experience. He is a M&A, regulatory, strategic, capital and capital markets expert. Allan has managed international finance and operations teams and sits on the board of directors for two technology companies and a public oil and gas corporation.
Neuritek’s vision is to bring next-generation psychiatric therapies to market for people suffering from psychiatric disorders, focusing initially on PTSD.
Neuritek Therapeutics is a biopharmaceutical company committed to developing revolutionary treatments with the potential to transform the lives of patients and families suffering from psychiatric disorders.
Built on years of research and clinical care of patients with PTSD, our goal is to develop the first mechanism-based treatment for PTSD. We do this through rigorous basic and clinical science, innovative research methodologies, and highly efficient clinical trial operations.
Novel treatment development for PTSD has been declared a priority by the Institute of Medicine, the United States Department of Defense, and the United States Department of Veterans Affairs.